Clinical Validations for IV-Cell™ and HemeScreen™ Completed
Precipio, Inc. (PRPO)
US:NASDAQ Investor Relations:
precipiodx.com/investors.html
Company Research
Source: GlobeNewswire
Orders expected from several major labs both domestically and internationally NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that as it approaches the end of Q3-2019, several of the large laboratories have successfully completed validation studies to test Precipio’s IV-Cell cytogenetics media product, as well as its HemeScreen Assay, and are proceeding towards placing orders. From Validation Testing To Revenue As previously discussed, each lab must undergo a complex and thorough process to introduce products such as IV-Cell cytogenetics media and HemeScreen Assay into its clinical work-flow. This includes extensive testing as well as side-by-side comparison to the laboratory’s existing process in order to ensure both consistent results, as well as superior performance of the products. Each potential customer has their unique acceptance procedures. Only once these and other important parameters are dem
Show less
Read more
Impact Snapshot
Event Time:
PRPO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRPO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRPO alerts
High impacting Precipio, Inc. news events
Weekly update
A roundup of the hottest topics
PRPO
News
- Precipio Announces Year end 2023 Shareholder Update CallGlobeNewswire
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY [Yahoo! Finance]Yahoo! Finance
- Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYGlobeNewswire
- Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for CancerGlobeNewswire
PRPO
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- PRPO's page on the SEC website